Your browser doesn't support javascript.
Comparison of Dose-Response Relationships for Two Isolates of SARS-CoV-2 in a Nonhuman Primate Model of Inhalational COVID-19.
Dabisch, Paul A; Sanjak, Jaleal S; Boydston, Jeremy A; Yeager, John; Herzog, Artemas; Biryukov, Jennifer; Beck, Katie; Do, Danh; Seman, Brittany G; Green, Brian; Bohannon, Jordan K; Holland, Brian; Miller, David; Ammons, Taylor; Freeburger, Denise; Miller, Susan; Jenkins, Tammy; Rippeon, Sherry; Miller, James; Clarke, David; Manan, Emmanuel; Patty, Ashley; Rhodes, Kim; Sweeney, Tina; Winpigler, Michael; Altamura, Louis A; Zimmerman, Heather; Hail, Alec S; Wahl, Victoria; Hevey, Michael.
  • Dabisch PA; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Sanjak JS; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.
  • Boydston JA; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Yeager J; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Herzog A; Censeo Insight, Seattle, Washington, USA.
  • Biryukov J; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Beck K; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Do D; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Seman BG; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Green B; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Bohannon JK; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Holland B; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Miller D; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Ammons T; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Freeburger D; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Miller S; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Jenkins T; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Rippeon S; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Miller J; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Clarke D; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Manan E; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Patty A; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Rhodes K; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Sweeney T; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Winpigler M; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Altamura LA; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Zimmerman H; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Hail AS; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Wahl V; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
  • Hevey M; National Biodefense Analysis and Countermeasures Center, Operated by Battelle National Biodefense Institute, U.S. Department of Homeland Security, Frederick, Maryland, USA.
J Aerosol Med Pulm Drug Deliv ; 2022 Nov 01.
Article in English | MEDLINE | ID: covidwho-2097255
ABSTRACT

Background:

As the COVID-19 pandemic has progressed, numerous variants of SARS-CoV-2 have arisen, with several displaying increased transmissibility.

Methods:

The present study compared dose-response relationships and disease presentation in nonhuman primates infected with aerosols containing an isolate of the Gamma variant of SARS-CoV-2 to the results of our previous study with the earlier WA-1 isolate of SARS-CoV-2.

Results:

Disease in Gamma-infected animals was mild, characterized by dose-dependent fever and oronasal shedding of virus. Differences were observed in shedding in the upper respiratory tract between Gamma- and WA-1-infected animals that have the potential to influence disease transmission. Specifically, the estimated median doses for shedding of viral RNA or infectious virus in nasal swabs were approximately 10-fold lower for the Gamma variant than the WA-1 isolate. Given that the median doses for fever were similar, this suggests that there is a greater difference between the median doses for viral shedding and fever for Gamma than for WA-1 and potentially an increased range of doses for Gamma over which asymptomatic shedding and disease transmission are possible.

Conclusions:

These results complement those of previous studies, which suggested that differences in exposure dose may help to explain the range of clinical disease presentations observed in individuals with COVID-19, highlighting the importance of public health measures designed to limit exposure dose, such as masking and social distancing. The dose-response data provided by this study are important to inform disease transmission and hazard modeling, as well as to inform dose selection in future studies examining the efficacy of therapeutics and vaccines in animal models of inhalational COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines / Variants Language: English Journal subject: Drug Therapy Year: 2022 Document Type: Article Affiliation country: Jamp.2022.0043

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines / Variants Language: English Journal subject: Drug Therapy Year: 2022 Document Type: Article Affiliation country: Jamp.2022.0043